The role of mucoprotectants in the management of gastrointestinal disorders

Expert Review of Gastroenterology and Hepatology

Volumn 12, Issue 1, 2018, Pages 83-90

  Eutamene, Helene ^a   Beaufrand, Catherine ^a   Harkat, Cherryl ^a   Theodorou, Vassilia ^a  

^a TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

Author keywords

Gelatin tannate; intestinal barrier; mucoprotectant; mucosal protectors; tight junctions; xyloglucan

Indexed keywords

AMINOSALICYLIC ACID; CORTICOSTEROID; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; GELATIN TANNATE; MUCIN; PLACEBO; PROBIOTIC AGENT; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; XYLOGLUCAN; DEMULCENT AGENT; GELATIN; GLUCAN; TANNATE GELATIN; TANNIN DERIVATIVE; XYLAN;

ANTIDIARRHEAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BACTEROIDES; DIARRHEA; DRUG MECHANISM; ENTERITIS; FIRMICUTES; GASTROINTESTINAL DISEASE; HUMAN; INFECTIOUS DIARRHEA; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; REVIEW; DRUG EFFECT; INTESTINE ABSORPTION; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERMEABILITY; TREATMENT OUTCOME;

DEMULCENTS; DIARRHEA; GELATIN; GLUCANS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; PERMEABILITY; TANNINS; TREATMENT OUTCOME; XYLANS;

EID: 85042423218     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2018.1378573     Document Type: Review

References (77)

1. Lopetuso LR, Scaldaferri F, Bruno G, et al. The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur Rev Med Pharmacol Sci. 2015;19(6):1068–1076.
2. Keita AV, Söderholm JD., The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil. 2010;22(7):718–733.
3. Catalioto RM, Maggi CA, Giuliani S. Intestinal epithelial barrier dysfunction in disease and possible therapeutical interventions. Curr Med Chem. 2011;18(3):398–426.
4. Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993;123(6 Pt 2):1777–1788.
5. Morita K, Furuse M, Fujimoto K, et al. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA. 1999;96(2):511–516.
6. Lu Z, Ding L, Lu Q, et al. Claudins in intestines: distribution and functional significance in health and diseases. Tissue Barriers. 2013;1(3):e24978.
7. Liu Y, Nusrat A, Schnell FJ, et al. Human junction adhesion molecule regulates tight junction resealing in epithelia. J Cell Sci. 2000;113(Pt 13):2363–2374.
8. Ikenouchi J, Furuse M, Furuse K, et al. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol. 2005;171(6):939–945.
9. Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol. 2012;1591:57–62.
10. Johansson ME, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10(6):352–361.
11. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4659–4665.
12. Johansson ME, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA. 2008;105(39):15064–15069.
13. Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science. 2011;334(6053):255–258.
14. Chu H, Pazgier M, Jung G, et al. Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science. 2012;337(6093):477–481.
15. Deloose E, Janssen P, Depoortere I, et al. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271–285.
16. Ouwerkerk JP, de Vos WM, Belzer C. Glycobiome: bacteria and mucus at the epithelial interface. Best Pract Res Clin Gastroenterol. 2013;27(1):25–38.
17. Kankainen M, Paulin L, Tynkkynen S, et al. Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human- mucus binding protein. Proc Natl Acad Sci USA. 2009;106(40):17193–17198.
18. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131(1):117–129.
19. Johansson ME, Gustafsson JK, Sjöberg KE, et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One. 2010;5(8):e12238.
20. Johansson ME, Gustafsson JK, Holmén-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014;63(2):281–291.
21. Jandhyala SM, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787–8803.
22. Gecse K, Róka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008;57(5):591–599.
23. Annaházi A, Ferrier L, Bézirard V, et al. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol. 2013;108(8):1322–1331.
24. Guttman JA, Finlay BB. Tight junctions as targets of infectious agents. Biochim Biophys Acta. 2009;1788(4):832–841.
25. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24(6):503–512.
26. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci (Landmark Ed). 2009;14:2765–2778.
27. Guttman JA, Lin AE, Li Y, et al. Gap junction hemichannels contribute to the generation of diarrhoea during infectious enteric disease. Gut. 2010;59(2):218–226.
28. Bijlsma PB, Bakker R, Groot JA. The chloride conductance of tight junctions of rat ileum can be increased by cAMP but not by carbachol. J Membr Biol. 1997;157(2):127–137.
29. Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut. 2003;52(2):218–223.
30. Li X, Wang Q, Xu H, et al. Somatostatin regulates tight junction proteins expression in colitis mice. Int J Clin Exp Pathol. 2014;7(5):2153–2162.
31. Ma TY, Nguyen D, Bui V, et al. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol. 1999;276(4 Pt 1):G965–G974.
32. Dokladny K, Moseley PL, Ma TY. Physiologically relevant increase in temperature causes an increase in intestinal epithelial tight junction permeability. Am J Physiol Gastrointest Liver Physiol. 2006;290(2):G204–G212.
33. Söderholm JD, Perdue MH. Stress and gastrointestinal tract. II. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol. 2001;280(1):G7–G13.
34. Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138(4):1502–1513.
35. Chen HQ, Yang J, Zhang M, et al. Lactobacillus plantarum ameliorates colonic epithelial barrier dysfunction by modulating the apical junctional complex and PepT1 in IL-10 knockout mice. Am J Physiol Gastrointest Liver Physiol. 2010;299(6):G1287–G1297.
36. Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology. 2009;136(2):551–563.
37. Fasano A, Fiorentini C, Donelli G, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest. 1995;96(2):710–720.
38. Bansal T, Alaniz RC, Wood TK, et al. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci U S A. 2010;107(1):228–233.
39. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469(7331):543–547.
40. Delgado ME, Grabinger T, Brunner T. Cell death at the intestinal epithelial front line. FEBS J. 2016;283(14):2701–2719.
41. Turcotte JF, Kao D, Mah SJ, et al. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc. 2013;77(4):624–630.
42. Viggiano D, Ianiro G, Vanella G, et al. Gut barrier in health and disease: focus on childhood. Eur Rev Med Pharmacol Sci. 2015;19(6):1077–1085.
43. Bürgel N, Bojarski C, Mankertz J, et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002;123(2):433–443.
44. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol. 2012;590(Pt 5):1035–1044.
45. Clayburgh DR, Barrett TA, Tang Y, et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest. 2005;115(10):2702–2715.
46. Troeger H, Epple HJ, Schneider T, et al. Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum. Gut. 2007;56(3):328–335.
47. Troeger H, Loddenkemper C, Schneider T, et al. Structural and functional changes of the duodenum in human norovirus infection. Gut. 2009;58(8):1070–1077.
48. Navaneethan U, Giannella RA. Mechanisms of infectious diarrhea. Nature Clin Prac. 2008;5(11):637–647.
49. Weber CR, Turner JR. Inflammatory bowel disease: is it really just another break in the wall? Gut. 2007;56(1):6–8.
50. Zeissig S, Bürgel N, Günzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut. 2007;56(1):61–72.
51. Maynard CL, Elson CO, Hatton RD, et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489(7415):231–241.
52. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145(5):745–757.
53. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–606.
54. Pitz AM, Park GW, Lee D, et al. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157: H7,norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93–100.
55. DuPont HL. Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm. 1987;21(9):687–693.
56. Frasca G, Cardile V, Puglia C, et al. Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells. Clin Exp Gastroenterol. 2012;5:61–67.
57. Ruszczyński M, Urbańska M, Szajewska H. Gelatin tannate for treating acute gastroenteritis: a systematic review. Ann Gastroenterol. 2014;27(2):121–124.
58. Scalbert A. Antimicrobial properties of tannins. Phytochemistry. 1991;30:3875–3883.
59. Ahn YJ, Lee CO, Kweon JH, et al. Growth-inhibitory effects of GallaRhois-derived tannins on intestinal bacteria. J Appl Microbiol. 1998;84(3):439–443.
60. Scaldaferri F, Lopetuso LR, Petito V, et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: emerging role for ‘gut barrier protectors’ in IBD? United European Gastroenterol J. 2014;2(2):113–122.
61. de Servi B, Moreira Da Silva R, Meloni M. New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 2: antibacterial activity [Abstract]. In: 33rd Congress of the Groupe Francophone d’Hépato-Gastroentérologie et Nutrition Pédiatriques; 2012 Mar 30; Nantes, France. Available from: www.tasectan.ie
62. Bueno L, Sekkal S, Theodorou V, et al. Undissociated gelatin tannate reduces intestinal leakiness and mucosa inflammation by forming a protective biofilm: results from in-vitro and in-vivo studies. United European Gastroenterol J. 2013;1(1 suppl):A75–A76.
63. Freli V, Moreira da Silva R, Pescio P. New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 1: film-forming effect [Abstract]. Archives pediatrie. 2013;20(5):549.
64. Bueno L, Theodorou V, Sekkal S. Xyloglucan: a new agent to protect the intestinal mucosa and to prevent bacterially-mediated alteration of tight junction permeability (Abstract). ueg journal. 2014;2(1sup):1675.
65. Gnessi L, Bacarea V, Marusteri M, et al. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol. 2015;15(1):153.
66. Durbán Reguera F, López-Argüeta Álvarez S, López Montes J, et al. Prospective observational study on adults with acute diarrhoea treated with gelatin tannate® [Abstract and poster]. In: Semana de las Enfermedades Digestivas Congress; 2007a Jun; Madrid, Spain. Available from: www.tasectan.ie/index.php/healthcare-professionals
67. Esteban Carretero J, Durbán Reguera F, López-Argüeta Alvarez S, et al. A comparative analysis of response to vs. ORS + gelatin tannate pediatric patients with acute diarrhea. Rev Esp Enferm Dig. 2009;101(1):41–48.
68. Durbán Reguera F, López-Argüeta Álvarez S, López Montes J, et al. Prospective observational study on infants and children with acute diarrhoea treated with gelatin tannate® [Abstract and poster]. Semana de las Enfermedades Digestivas Congress; 2007b Jun; Madrid, Spain. Available from: www.tasectan.ie/index.php/healthcare-professionals
69. Allegrini A, Costantini M. Gelatine tannate for the treatment of acute diarrhoea in adults. J Gastroint Dig Syst. 2012;2:3.
70. Aloi M, Pofi F, Tolone C, et al. Gelatin tannate as treatment for acute diarrhea in children: a prospective, randomized, parallel study. Dig Liver Dis. 2013;45(Suppl 4):e279.
71. Allegrini A, Costantini M. TASECTANTM (Gelatin tannate) for the treatment of acute gastroenteritis in children: preliminary results from a study conducted to evaluate its efficacy and safety [Abstract and poster]. 39th Annual Belgium Paediatric Society Congress; 2011 Mar; Brussels, Belgium. Available from: www.tasectan.ie/index.php/healthcare-professionals
72. Guzganu IL. Severe diarrhea in a 4-month-old baby girl with acute gastroenteritis: a case report and review of the literature. Case Rep Gastrointest Med. 2012;2012:920375.
73. Condratovici CP, Bacarea V, Piqué N. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, clinical trial. Gastroenterol Res Pract. 2016;2016:6874207.
74. Farthing M, Salam MA, Lindberg G, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013;47(1):12–20.
75. Faure C. Role of antidiarrhoeal drugs as adjunctive therapies for acute diarrhoea in children. Int J Pediatr. 2013;2013:612403.
76. Franceschi F, Scaldaferri F, Riccioni ME, et al. Management of acute dyarrhea: current and future trends. Eur Rev Med Pharmacol Sci. 2014;18(14):2065–2069.
77. Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med. 2007;4(3):e98.